Infectologia

Cães farejadores na detecção de COVID-19: estudo randomizado triplo-cego em ambiente aeroportuário.

19 Mai, 2022 | 13:14h

Scent dogs in detection of COVID-19: triple-blinded randomised trial and operational real-life screening in airport setting – BMJ Global Health

Comunicado de imprensa: Trained sniffer dogs accurately detect people infected with SARS-CoV-2 – BMJ Newsroom

Comentário: Trained scent dogs detect airline travelers with COVID-19 – CIDRAP

---

[Preprint] Efetividade do segundo reforço da vacina contra COVID-19 sobra a mortalidade por todas as causas em residentes de instituições de cuidado de longo prazo e em idosos mais velhos: estudo nacional de coorte retrospectiva na Suécia.

19 Mai, 2022 | 13:13h

Effectiveness of a Second COVID-19 Vaccine Booster on All-Cause Mortality in Long-Term Care Facility Residents and in the Oldest Old: A Nationwide, Retrospective Cohort Study in Sweden – Preprints with The Lancet

 

Comentário no Twitter

Confirmation of the 2nd booster protection from death in people age 80+ in Sweden, with a relative vaccine effectiveness 42% (compared w/ the 1st booster)https://t.co/Dq1x00J3Tr pic.twitter.com/fyXJPEcQzC

— Eric Topol (@EricTopol) May 17, 2022

 

---

Tratamento das interações medicamentosas com nirmatrelvir/ritonavir (Paxlovid).

19 Mai, 2022 | 13:08h

Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians – Infectious Diseases Society of America

Comentário: IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir – ACP Internist

Conteúdos relacionados:

Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic – STAT

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

---

Diretrizes | Tratamento de infecções recorrentes de trato urinário em mulheres.

19 Mai, 2022 | 13:07h

Guideline of guidelines: management of recurrent urinary tract infections in women – BJU International

---

Atualização clínica da COVID-19 para o médico emergencista: parada cardíaca dentro e fora do ambiente hospitalar.

18 Mai, 2022 | 17:01h

Clinical update on COVID-19 for the emergency clinician: Cardiac arrest in the out-of-hospital and in-hospital settings – The American Journal of Emergency Medicine

Conteúdos relacionados:

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management – American Journal of Emergency Medicine

Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation – The American Journal of Emergency Medicine

---

Estudo RECOVERY | Por questões de segurança, o recrutamento de pacientes com Covid-19 apresentando hipóxia sem oxigênio ou recebendo oxigênio simples para doses mais altas de corticosteroides foi encerrado.

18 Mai, 2022 | 17:00h

Recruitment to higher dose corticosteroids closed for patients with hypoxia on no oxygen or receiving simple oxygen – University of Oxford

---

Estudo de coorte | Trombose venosa ou arterial e mortes em casos de COVID-19.

18 Mai, 2022 | 16:58h

Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study – The Lancet Infectious Diseases

Comentário convidado: Risk of arterial and venous thromboses after COVID-19 – The Lancet Infectious Diseases

Comunicado de imprensa: COVID-19’s high blood clot risk – University of Oxford

 

Comentário no Twitter

Clots with Covid: Multi-national report of over 900,000 people indicates propensity of risk for arterial and venous thrombi is in men, with increasing age, and association with fatalities (4-fold in non-hospitalized) https://t.co/muGnDld4Um pic.twitter.com/6bLiHPLInm

— Eric Topol (@EricTopol) May 13, 2022

Sob licença de Creative Commons Attribution (CC BY 4.0)

---

Estudo de coorte | Risco de morte e reinternação não planejada após alta hospitalar de internação por COVID-19.

18 Mai, 2022 | 16:56h

The risk of death or unplanned readmission after discharge from a COVID-19 hospitalization in Alberta and Ontario – Canadian Medical Association Journal

Comentário: Study: Readmission rate for COVID-19 is 11% – CIDRAP

---

Estudo randomizado | Antibioticoprofilaxia de longa duração na amputação de membro inferior.

18 Mai, 2022 | 16:49h

Extended-course antibiotic prophylaxis in lower limb amputation: randomized clinical trial – British Journal of Surgery (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

In the May issue of BJS: Extended-course antibiotic prophylaxis in lower limb amputation: randomized clinical trial https://t.co/2H0TthufvZ @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs pic.twitter.com/taSa4Caibn

— BJS (@BJSurgery) April 30, 2022

 

---

Comentário de estudo | Antibióticos para pneumonia pediátrica: menos pode ser suficiente?

18 Mai, 2022 | 16:42h

Antibiotics for Pediatric Pneumonia: Might Less Be Enough? – Annals of Emergency Medicine

Estudo original: Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial – JAMA

Conteúdos relacionados:

Extended Versus Standard Antibiotic Course Duration in Children <5 Years of Age Hospitalized With Community-acquired Pneumonia in High-risk Settings: Four-week Outcomes of a Multicenter, Double-blind, Parallel, Superiority Randomized Controlled Trial – The Pediatric Infectious Disease Journal

Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial – JAMA Pediatrics

Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians – Annals of Internal Medicine

Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial – JAMA Pediatrics

Treatment of UTIs in Infants <2 Months: A Living Systematic Review – Hospital Pediatrics

Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial – JAMA

Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial – Clinical Infectious Diseases

Efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults: A systematic review and meta-analysis – Antimicrobial Agents and Chemotherapy

---